Pressure BioSciences (PBIO) 10-K2019 FY Annual report

Filed: 14 Apr 20, 5:29pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Abbvie, absenteeism, acclaimed, acknowledged, adjacent, agglomeration, Allergan, Amgen, amino, article, attached, Baro, BaroShear, batch, beer, benchtop, beverage, bioactive, Biocon, Biomanufacturing, biophysical, Biopolymer, bloodstream, boost, border, broadly, carbohydrate, care, Caspase, Catalent, Cathepsin, Centre, chance, Christine, Christopher, CIP, Clerk, Confession, confirming, contractor, conventional, counteracting, Dan, Daniel, degradation, Delaware, destroy, disentangle, diverse, double, downturn, driven, entrance, era, Erythropoietin, excised, EXT, factory, faith, fate, feasibility, fewer, fingerprint, Fisher, forbearance, formulation, forty, foster, Fujifilm, Fusion, GE, German, glycosylation, GMP, great, grown, gynecologic, gynecological, harsh, HGH, highest, hope, Hospira, HPP, huge, hydrophobic, ideally, IGNG, illustrated, imaging, immiscible, immune, immunogenic, immunogenicity, imposition, inactive, inclusion, inefficient, inferior, inflammatory, infused, Inova, inside, insoluble, instantly, insulin, interfering, investigate, irreversible, journal, Judgement, Korea, laboratoriesinvolved, landing, learning, legend, lethal, logging, Lonza, lost, macroeconomic, Magazine, magnitude, mapping, Max, maximal, Mayo, Merck, milder, Mini, misshapen, mission, mode, Momenta, monoclonal, movement, multiplied, Mylan, nano, nanoemulsification, NanoPeak, nationwide, nutraceutical, NutraLife, NYU, outbreak, overdose, Overexpression, patient, PBl, perfecting, persuade, Pfizer, pivotal, Police, popular, potent, predominant, predominantly, prognostic, random, receptor, recombinant, RedShift, RedShiftBio, refund, reiterated, resolve, restructuring, revolutionize, roadblock, rollout, routing, safer, Samsung, Sandoz, Sanofi, Schar, seasoned, seeding, sellout, Shea, shock, solubilization, soluble, sophisticated, spiked, standing, Standstill, stemming, stochastic, suboptimal, supply, supplying, synergy, tailored, Takeda, technician, TheCompany, theoretical, ThePBI, thermal, Thermo, timeframe, traditional, trajectory, travel, Treasurer, turn, turning, unmet, untreatable, valve, verbal, vibration, visibility, Vogel, witnessing, worker

Removed: addictive, amounting, AQualified, Army, arthropod, assembly, Atomic, BaroFlex, BaroFlexTM, bifurcate, binomial, BioCompare, capped, carrier, Central, chamber, classic, compound, consolidate, contracted, counter, dated, declined, density, eating, embedded, enrichment, enzyme, foregoing, fragmentation, governing, HDPE, Hedging, horsepower, HPLC, hydrodynamic, incubation, Innovation, internally, isoform, ix, joined, keypad, motor, NASDAQ, Nathan, noting, origination, output, passed, pharmacological, pipeline, polyethylene, procedure, proxy, pump, retrospectively, round, Scenario, seal, showing, silicone, submitting, thirty, tightly, Transparency, trypsin, universal, unused, view, viii, weigh, whichever, worth, xi, XstreamPCT

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PBIO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

In connection with the Annual Report on Form 10-K of Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”) for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Richard T. Schumacher, Chief Financial Officer, of Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”), do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) that:

(1) The Report of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: April 14, 2020

/s/ Richard T. Schumacher

Richard T. Schumacher

Interim Chief Financial Officer

(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to Pressure BioSciences, Inc., and will be retained by Pressure BioSciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.